Can Lexapro (escitalopram) be used as an adjunctive treatment for depressive symptoms in patients with bipolar depression who are already on a mood stabilizer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Use of Escitalopram for Bipolar Depression with Mood Stabilizer

Escitalopram should not be used as first-line treatment for bipolar depression, even with a mood stabilizer on board, due to the risk of triggering manic/hypomanic episodes and lack of proven superior efficacy compared to mood stabilizer optimization alone. 1, 2

Risks of Antidepressants in Bipolar Disorder

Antidepressants in bipolar disorder carry significant risks:

  • The FDA label for escitalopram specifically warns about the risk of activation of mania/hypomania in patients with bipolar disorder 2
  • Escitalopram can precipitate a mixed/manic episode in patients with bipolar disorder, even when used with mood stabilizers 2
  • The risk of treatment-emergent affective switch is a serious concern, with some antidepressants showing higher switch rates than others 3

Evidence on Efficacy

The evidence for adding antidepressants to mood stabilizers in bipolar depression is not compelling:

  • A high-quality study found that adjunctive antidepressant therapy was not associated with increased efficacy compared to mood stabilizer alone (23.5% vs 27.3% durable recovery rates) 4
  • While a small open-label study of escitalopram showed some benefit, it also reported concerning adverse events including manic switch (1 patient), hypomanic symptoms (2 patients), and hospitalization due to suicidal ideation (1 patient) out of 20 participants 5

Preferred Treatment Algorithm

  1. First-line options:

    • Optimize current mood stabilizer dosing
    • Consider quetiapine or olanzapine as add-on therapy 6
    • Consider lamotrigine as add-on therapy, especially if the patient is already on lithium 1, 6
  2. Second-line options:

    • If the above strategies fail, consider short-term use of an antidepressant with lower switch risk (bupropion or sertraline) rather than venlafaxine or escitalopram 3
    • Add evidence-based psychotherapy (cognitive-behavioral therapy) 1
  3. Monitoring requirements if escitalopram is used:

    • Screen for personal or family history of bipolar disorder, mania, or hypomania before initiating treatment 2
    • Monitor closely for signs of mania/hypomania (increased energy, decreased need for sleep, racing thoughts, impulsivity)
    • Regular assessment for suicidal ideation
    • Gradual dose reduction if discontinuation is needed 2

Important Caveats

  • Patients with rapid-cycling bipolar disorder may be at particularly high risk for mood switches with antidepressants 1
  • If escitalopram must be used, it should always be in combination with a mood stabilizer, never as monotherapy 1
  • Maintenance therapy with mood stabilizers is often needed for 12-24 months or longer after episode resolution 7
  • Polypharmacy is common in bipolar disorder treatment but should be approached cautiously to minimize side effects 7

In conclusion, while escitalopram can technically be used as adjunctive therapy for bipolar depression with a mood stabilizer on board, the evidence suggests this approach carries significant risks without clear evidence of superior efficacy compared to optimizing mood stabilizer therapy or using other evidence-based adjunctive treatments.

References

Guideline

Management of Bipolar Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.

The British journal of psychiatry : the journal of mental science, 2006

Research

An open trial of adjunctive escitalopram in bipolar depression.

The Journal of clinical psychiatry, 2006

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.